Is sertraline an maoi
Pro Research Analysisby 
Searched over 200M research papers
Is Sertraline an MAOI?
Understanding Antidepressant Classes: SSRIs vs. MAOIs
Antidepressants are categorized into several classes based on their mechanisms of action. Two of these classes are Selective Serotonin Reuptake Inhibitors (SSRIs) and Monoamine Oxidase Inhibitors (MAOIs). SSRIs, such as sertraline, function by increasing the levels of serotonin in the brain by inhibiting its reuptake into neurons. On the other hand, MAOIs work by inhibiting the activity of monoamine oxidase, an enzyme responsible for breaking down neurotransmitters like serotonin, norepinephrine, and dopamine.
Sertraline: A Selective Serotonin Reuptake Inhibitor (SSRI)
Sertraline is widely recognized as an SSRI, not an MAOI. It is commonly prescribed for the treatment of depression and other mood disorders due to its efficacy and relatively favorable side effect profile. Unlike MAOIs, sertraline does not inhibit the monoamine oxidase enzyme but rather prevents the reuptake of serotonin, thereby increasing its availability in the synaptic cleft1 3 5.
Safety and Efficacy of Sertraline
Sertraline is often preferred over other antidepressants, especially in populations with comorbid conditions such as cardiovascular disease and diabetes. Its safety profile is well-documented, showing fewer cardiovascular side effects compared to tricyclic antidepressants (TCAs) and MAOIs. For instance, sertraline is considered a safer option for patients with ischemic heart disease due to its low risk of drug-drug interactions and adverse cardiovascular effects1. Additionally, in diabetic patients, SSRIs like sertraline are preferred over TCAs and MAOIs due to their favorable impact on glucose metabolism and lower risk of inducing hypoglycemia3.
Sertraline in Special Populations
In elderly patients, sertraline is often the SSRI of choice due to its consistent pharmacokinetics across different age groups and lower potential for drug-drug interactions. Unlike fluoxetine and paroxetine, which can lead to higher plasma levels in elderly patients, sertraline maintains stable plasma levels, making it a safer option for this demographic5.
Conclusion
In summary, sertraline is an SSRI, not an MAOI. It is widely used for its efficacy in treating depression and other mood disorders, with a favorable safety profile that makes it suitable for use in patients with comorbid conditions such as cardiovascular disease and diabetes, as well as in elderly patients. Its mechanism of action, which involves the inhibition of serotonin reuptake rather than monoamine oxidase, distinguishes it clearly from MAOIs.
Sources and full results
Most relevant research papers on this topic
Treatment of Depression in Patients with Concomitant Cardiac Disease.
Antidepressants should be carefully selected for patients with concomitant cardiac disease, considering potential CV risks and balancing safety and efficacy.
Systematic ReviewTricyclic antidepressant pharmacology and therapeutic drug interactions updated
Nortriptyline and desipramine are the most effective tricyclic antidepressants, with clomipramine being the only drug with clinically relevant serotonin and noradrenaline reuptake inhibition.
Highly CitedTreatment of depression in patients with diabetes mellitus.
Depression is common in diabetic patients and impairs diabetic management, so SSRIs should be considered over TCAs for optimal treatment.
Systematic ReviewHighly CitedSertraline inhibits increases in body fat and carbohydrate dysregulation in adult female cynomolgus monkeys
Chronic SSRI use prevents increases in body weight, fat, insulin, and HOMA-IR in adult female cynomolgus monkeys, but may negatively affect adiponectin levels, potentially affecting cardiovascular health.
RCT
Animal StudyRecent pharmacologic advances in antidepressant therapy for the elderly.
SSRIs are the most effective and safe antidepressant choice for elderly depression patients due to their broad spectrum of activity, wide therapeutic index, and absence of serious adverse effects.
Highly CitedHuman therapeutic plasma levels of the selective serotonin reuptake inhibitor (SSRI) sertraline decrease serotonin reuptake transporter binding and shelter-seeking behavior in adult male fathead minnows.
Sertraline exposure in adult male fathead minnows leads to decreased serotonin reuptake transporter binding and shelter-seeking behavior, suggesting potential ecological consequences for aquatic vertebrates.
Highly CitedAquatic ecotoxicity of the selective serotonin reuptake inhibitor sertraline hydrochloride in a battery of freshwater test species.
Sertraline hydrochloride negatively affects aquatic organisms at levels several orders of magnitude higher than reported in municipal effluent concentrations, with potential effects from lower concentration exposures.
Highly CitedSertraline: a review of its use in the management of major depressive disorder in elderly patients.
Sertraline is an effective and well-tolerated antidepressant for elderly patients with major depressive disorder, offering benefits over nortriptyline and fluoxetine without affecting antidepressant effects.
Literature ReviewClinical Pharmacokinetics of Sertraline
Sertraline is a well-tolerated and relatively safe antidepressant with minimal inhibitory effects on major cytochrome P450 enzymes and few drug-drug interactions.
Highly CitedEffects of sertraline on autonomic and cognitive functions in healthy volunteers
Sertraline reduces heart rate and skin conductance levels without altering cognitive or psychomotor performance in healthy humans, possibly due to a sympatho-inhibitory effect.
RCTHighly Cited